Placebo for AMG 133
Sponsors
Amgen Inc.
Conditions
"Moderate to severe obstructive sleep apnea (OSA) in adults living with overweight or obesity"Chronic Weight ManagementOverweight and ObesityType 2 Diabetes Mellitus
Phase 2
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus.
CompletedCTIS2023-510470-13-00
Start: 2023-03-10End: 2025-10-14Target: 135Updated: 2026-01-26
A Phase 2 Randomized, Double-blind, Placebo‑controlled, Dose‑ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mellitus
Active, not recruitingCTIS2024-513539-25-00
Start: 2024-11-22Target: 169Updated: 2025-09-25
Phase 3
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-1)
Not yet recruitingCTIS2025-522703-14-00
Target: 45Updated: 2026-02-10
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight
Not yet recruitingCTIS2026-525408-82-00
Target: 184Updated: 2026-09-22